IN2012DN00605A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00605A
IN2012DN00605A IN605DEN2012A IN2012DN00605A IN 2012DN00605 A IN2012DN00605 A IN 2012DN00605A IN 605DEN2012 A IN605DEN2012 A IN 605DEN2012A IN 2012DN00605 A IN2012DN00605 A IN 2012DN00605A
Authority
IN
India
Prior art keywords
4alkyl
hydrogen
taken together
dioxolane
alkyl
Prior art date
Application number
Inventor
R Pendri Yadagiri
H Chen Chung-Pin
S Patel Sunil
M Evans Jeffrey
Liang Jing
R Kronenthal David
L Powers Gerald
Josyula Prasad Siva
T Bien Jeffrey
Shi Zhongping
N Patel Ramesh
Banerjee Amit
Y Chan Yeung
K Rijhwani Sushil
K Singh Ambarish
Wang Shaopeng
Stojanovic Milan
J Kucera David
Polniaszek Richard
Lewis Charles
Thottathil John
Krishnamurty Dhileepkumar
X Zhou Maotang
Vemishetti Purushotham
Original Assignee
Bristol Mayers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Mayers Squibb Company filed Critical Bristol Mayers Squibb Company
Publication of IN2012DN00605A publication Critical patent/IN2012DN00605A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/0825—Preparations of compounds not comprising Si-Si or Si-cyano linkages
    • C07F7/083—Syntheses without formation of a Si-C bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/0825—Preparations of compounds not comprising Si-Si or Si-cyano linkages
    • C07F7/0827—Syntheses with formation of a Si-C bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

A compound of formula: or a salt thereof wherein: Ra is alkyl, phenyl, C1 to C6 alkylphenyl, or C1 to C6 alkoxyphenyl; Rb is C1 to C6 alkyl; R20 is hydrogen or benzyl; X is C1, I, or benzyloxy; Ry and Rz are taken together to form, methylene (=CH2), or Ry is OR23, and Rz is -CH2OR24, wherein R23 and R24 are each hydrogen or are taken together to form a ting to define a dioxolane, said dioxolane being optionally substituted with -O(C1-4alkyl) or-O(C=O)( C1-4alkyl); and R25 and R26 are both hydrogen, or one of R23 and R26 is hydrogen and the other is acyl; or R25 and R26are taken together to form =CH(OC1-4alkyl) or =CH(OC(=O)C1-4alkyl).
IN605DEN2012 2002-12-11 2003-12-10 IN2012DN00605A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43254902P 2002-12-11 2002-12-11
PCT/US2003/039554 WO2004052310A2 (en) 2002-12-11 2003-12-10 Process and intermediates for synthesis entecavir

Publications (1)

Publication Number Publication Date
IN2012DN00605A true IN2012DN00605A (en) 2015-06-12

Family

ID=32507962

Family Applications (3)

Application Number Title Priority Date Filing Date
IN604DEN2012 IN2012DN00604A (en) 2002-12-11 2003-12-10
IN606DEN2012 IN2012DN00606A (en) 2002-12-11 2003-12-10
IN605DEN2012 IN2012DN00605A (en) 2002-12-11 2003-12-10

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IN604DEN2012 IN2012DN00604A (en) 2002-12-11 2003-12-10
IN606DEN2012 IN2012DN00606A (en) 2002-12-11 2003-12-10

Country Status (18)

Country Link
US (3) US7034152B2 (en)
EP (2) EP2433941A1 (en)
JP (2) JP4726491B2 (en)
KR (2) KR101096830B1 (en)
CN (6) CN101899063B (en)
AU (1) AU2003300884B2 (en)
BR (2) BRPI0317255B8 (en)
CA (2) CA2508811C (en)
DK (1) DK1644384T3 (en)
ES (1) ES2397104T3 (en)
IL (1) IL168691A (en)
IN (3) IN2012DN00604A (en)
MX (1) MXPA05005971A (en)
PL (2) PL212790B1 (en)
PT (1) PT1644384E (en)
SI (1) SI1644384T1 (en)
TW (1) TWI327568B (en)
WO (1) WO2004052310A2 (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2488562A1 (en) * 2002-06-27 2004-01-08 F. Hoffmann-La Roche Ag Synthesis of purine derivatives
IN2012DN00604A (en) * 2002-12-11 2015-08-21 Bristol Myers Squibb Co
TW200540175A (en) * 2004-06-04 2005-12-16 Bristol Myers Squibb Co Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
US7511139B2 (en) 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
CN100379736C (en) * 2005-05-13 2008-04-09 上海仲夏化学有限公司 Preparation process of entecavir
CN1699366A (en) * 2005-06-03 2005-11-23 北京市典范科技有限责任公司 Purine derivatives
US20070060599A1 (en) * 2005-09-09 2007-03-15 Dimarco John D Crystalline forms of [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
CN101863842B (en) * 2006-08-24 2012-02-01 江苏正大天晴药业股份有限公司 Entecavir midbodies and synthesis method
CN101838270B (en) * 2006-08-24 2012-04-18 江苏正大天晴药业股份有限公司 Intermediates of Entecavir and preparation thereof
CN101838207B (en) * 2006-08-24 2012-04-25 江苏正大天晴药业股份有限公司 Intermediates of Entecavir and synthesis method thereof
CN101130542B (en) * 2006-08-24 2010-08-04 江苏正大天晴药业股份有限公司 Synthesis method of antiviral nucleoside analogue
US8299152B2 (en) * 2006-10-30 2012-10-30 Pirelli Tyre S.P.A. Tire for vehicle wheels comprising crosslinked elastomeric composition
CN101245068A (en) * 2007-02-14 2008-08-20 浙江医药股份有限公司新昌制药厂 Crystallization type entecavir, method of producing the same, pharmaceutical composition and uses thereof
CN101371841A (en) * 2007-08-23 2009-02-25 浙江医药股份有限公司新昌制药厂 Crystallization type Entecavir formulation as well as preparation method and use thereof
CN101284799B (en) 2007-03-23 2013-04-03 浙江医药股份有限公司新昌制药厂 Nitrogen-contained derivates of caffeoylquinic acid, method for preparing same, pharmaceutical compositions thereof and uses
CN101074217B (en) * 2007-04-04 2010-11-24 北京精华耀邦医药科技有限公司 Method for obtaining endicawil critical intermediate by chromatogram separation
CN101397333A (en) 2007-09-27 2009-04-01 浙江医药股份有限公司新昌制药厂 De-hydroxyl vancomycin, preparation method thereof, medicament composition and use thereof
CN101723945B (en) * 2008-10-17 2011-11-02 上海清松制药有限公司 Method for preparing antiviral medicinal entecavir intermediate
KR101150254B1 (en) 2008-12-26 2012-06-12 한미사이언스 주식회사 Process for preparing entecavir and intermediates used therein
CN101828693B (en) 2009-03-09 2013-01-02 浙江医药股份有限公司新昌制药厂 Preparation method and application of low-viscosity high-fluidity carotenoid oil suspension
CN101531660B (en) * 2009-04-14 2012-07-04 安徽贝克联合制药有限公司 Industrialization production process of entecavir-monohydrate
CA2777018C (en) * 2009-10-12 2014-04-29 Hanmi Holdings Co., Ltd. Novel method for preparing entecavir and intermediate used therein
CN101693713B (en) * 2009-10-28 2011-11-09 福建广生堂药业有限公司 New crystal system of entecavir, preparation process and medicament application thereof
CN101781301B (en) * 2010-01-15 2013-04-10 复旦大学 Method for preparing entecavir
US8481728B2 (en) * 2010-02-16 2013-07-09 Scinopharm Taiwan, Ltd. Process for preparing entecavir and its intermediates
CN101805339B (en) * 2010-04-12 2012-01-11 王明 Entecavir compound preparation method
CA2705953C (en) 2010-05-31 2018-05-01 Alphora Research Inc. Carbanucleoside synthesis and intermediate compounds useful therein
CN101891741B (en) * 2010-07-06 2013-01-23 苏州汉德森医药科技有限公司 New synthesis process of antiviral drug entecavir
CN102336754B (en) 2010-07-15 2017-04-12 浙江奥翔药业股份有限公司 Method for synthesizing entecavir and intermediate compound thereof
TWI588146B (en) * 2010-08-30 2017-06-21 浙江奧翔藥業股份有限公司 Synthetic method of entecavir and intermediate compounds thereof
EP2474548A1 (en) 2010-12-23 2012-07-11 Esteve Química, S.A. Preparation process of an antiviral drug and intermediates thereof
KR101269491B1 (en) * 2010-12-23 2013-05-31 주식회사 한서켐 Preparation method for entecavir
CN102225938A (en) * 2011-04-25 2011-10-26 海南卫康制药(潜山)有限公司 Novel synthesis process of entecavir monohydrate
CN102267875B (en) * 2011-06-17 2013-04-24 常州寅盛药业有限公司 Preparation method of entecavir intermediate
CN102952156A (en) * 2011-08-29 2013-03-06 南京工业大学 Anti-hepatitis B drug entecavir intermediate and synthesis thereof
CN102952135B (en) * 2011-08-31 2015-04-08 南京工业大学 Synthesis method for medicine entecavir for treating hepatitis B
EP2597096A1 (en) 2011-11-24 2013-05-29 Esteve Química, S.A. Process for preparing entecavir and intermediates thereof
CN103304375B (en) * 2012-03-12 2017-04-12 浙江奥翔药业股份有限公司 Synthesis intermediate of Entecavir and preparation method thereof
RU2651570C2 (en) 2012-10-02 2018-04-23 Кэлифорниа Инститьют Оф Текнолоджи Transition-metal-free silylation of aromatic compounds
US9908840B2 (en) 2012-10-02 2018-03-06 California Institute Of Technology Reactions of aromatic substrates with base-activated hydrosilanes-silylations and reductive cleavage
CN104017015B (en) * 2013-02-28 2017-04-05 浙江星月药物科技股份有限公司 The preparation method of the intermediate of one class Entecavir, and intermediate
CN104017016B (en) * 2013-02-28 2017-04-05 浙江星月药物科技股份有限公司 The preparation method of the intermediate of one class Entecavir, and intermediate
CN104017012A (en) * 2013-02-28 2014-09-03 浙江星月药物科技股份有限公司 Entecavir intermediates and preparation method thereof
CN104017014A (en) * 2013-02-28 2014-09-03 浙江星月药物科技股份有限公司 Entecavir intermediates and preparation method thereof
CN104016984A (en) * 2013-02-28 2014-09-03 浙江星月药物科技股份有限公司 Entecavir, intermediates thereof and preparation methods of Entecavir and intermediates thereof
CN104177396A (en) * 2013-05-23 2014-12-03 浙江星月药物科技股份有限公司 Entecavir intermediates and preparation methods thereof
CN104177397B (en) * 2013-05-23 2017-10-13 浙江星月药物科技股份有限公司 Entecavir midbodies and preparation method thereof
CN104177394B (en) * 2013-05-23 2017-12-05 浙江星月药物科技股份有限公司 Entecavir midbodies and preparation method thereof
GB201313238D0 (en) 2013-07-24 2013-09-04 Avexxin As Process for the preparation of a polyunsaturated ketone compound
EP3536694B1 (en) * 2014-08-06 2020-12-02 California Institute of Technology Silylation of aromatic heterocycles by earth abundant transition-metal-free catalysts
KR101640503B1 (en) 2015-04-15 2016-07-18 동방에프티엘(주) Improved process for the preparation of entecavir Monohydrate
KR101640504B1 (en) 2015-04-15 2016-07-18 동방에프티엘(주) Novel process of Entecavir monohydrate
CN105037363B (en) * 2015-07-13 2016-08-24 山东罗欣药业集团股份有限公司 A kind of entecavir compound prepared novel synthesis
CN108884005B (en) * 2016-04-07 2021-11-12 佐治亚大学研究基金会 Synthesis of 2 '-fluoro-6' -methylene-carbocyclic adenosine (FMCA) and 2 '-fluoro-6' -methylene-carbocyclic guanosine (FMCG)
CN107325122B (en) * 2017-01-06 2020-05-01 常州博海威医药科技股份有限公司 Novel intermediate for preparing prostaglandins and preparation method thereof
CN107163049B (en) * 2017-05-31 2019-06-18 湖北远大生命科学与技术有限责任公司 A kind of preparation method of Entecavir
WO2019080686A1 (en) * 2017-10-26 2019-05-02 广州市朗启医药科技有限责任公司 Entecavir intermediate and synthesis method therefor, and method for synthesizing entecavir
CN109705063B (en) 2017-10-26 2021-01-01 广州市朗启医药科技有限责任公司 Entecavir intermediate and synthetic method thereof, and synthetic method of entecavir
CN109232637B (en) * 2018-10-29 2020-11-24 常州博海威医药科技股份有限公司 Preparation method of entecavir intermediate
CN109593090A (en) * 2019-01-25 2019-04-09 连云港贵科药业有限公司 A kind of synthetic method of Entecavir
CN112625041A (en) * 2020-12-25 2021-04-09 常州博海威医药科技股份有限公司 Novel preparation method and intermediate of entecavir

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4594439A (en) 1980-08-06 1986-06-10 The Board Of Trustees Of The Leland Stanford Jr. University Method for asymmetric epoxidation
US4471130A (en) 1980-08-06 1984-09-11 The Board Of Trustees Of The Leland Stanford Junior University Method for asymmetric epoxidation
US4900847A (en) 1985-04-04 1990-02-13 Massachusetts Institute Of Technology Catalytic asymmetric epoxidation
JPH01207257A (en) * 1988-02-15 1989-08-21 Nippon Oil & Fats Co Ltd Method for separating alpha-linolenic acid
US5206244A (en) * 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
EP0630897A3 (en) * 1993-06-25 1995-03-01 Bristol Myers Squibb Co 3-Hydroxy-4-hydroxymethyl-2-methylene-cyclopentyl purines and pyrimidines.
US5665890A (en) * 1995-03-14 1997-09-09 President And Fellows Of Harvard College Stereoselective ring opening reactions
WO1998009964A1 (en) * 1996-09-03 1998-03-12 Bristol-Myers Squibb Company IMPROVED PROCESS FOR PREPARING THE ANTIVIRAL AGENT [1S-(1α, 3α, 4β)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE
US6127159A (en) * 1997-06-06 2000-10-03 The Board Of Trustees Of The Leland Stanford Junior University Mitofusin genes and their uses
BRPI0108435B8 (en) * 2000-02-29 2021-05-25 Bristol Myers Squibb Co formulation and use of low-dose entecavir
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
ES2319732T3 (en) * 2000-04-13 2009-05-12 Pharmasset, Inc. DERIVATIVES OF NUCLEOSIDE 3'- OR 2'-HYDROXIMETHYL REPLACED FOR THE TREATMENT OF VIRAL INFECTIONS.
IN2012DN00604A (en) * 2002-12-11 2015-08-21 Bristol Myers Squibb Co
US7511139B2 (en) * 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
US20070060599A1 (en) * 2005-09-09 2007-03-15 Dimarco John D Crystalline forms of [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one

Also Published As

Publication number Publication date
JP2010222365A (en) 2010-10-07
CN101130552B (en) 2010-07-28
DK1644384T3 (en) 2013-02-11
TWI327568B (en) 2010-07-21
CN101130543B (en) 2011-06-08
EP1644384A2 (en) 2006-04-12
CN102675355B (en) 2015-05-06
PL397715A1 (en) 2012-03-26
JP4726491B2 (en) 2011-07-20
CA2508811A1 (en) 2004-06-24
CN100379746C (en) 2008-04-09
IN2012DN00604A (en) 2015-08-21
CN101130552A (en) 2008-02-27
BR122019020833B8 (en) 2021-07-27
CN101130543A (en) 2008-02-27
KR20090084979A (en) 2009-08-05
CN1747959A (en) 2006-03-15
AU2003300884A1 (en) 2004-06-30
JP2006509800A (en) 2006-03-23
AU2003300884B2 (en) 2010-01-21
US20060106215A1 (en) 2006-05-18
PL212790B1 (en) 2012-11-30
US20040192912A1 (en) 2004-09-30
EP2433941A1 (en) 2012-03-28
EP1644384A4 (en) 2009-09-02
TW200504065A (en) 2005-02-01
BRPI0317255B1 (en) 2019-12-24
CN104788485B (en) 2017-10-03
IN2012DN00606A (en) 2015-06-12
CN104788485A (en) 2015-07-22
WO2004052310A3 (en) 2005-03-03
ES2397104T3 (en) 2013-03-04
CN101899063A (en) 2010-12-01
US7541460B2 (en) 2009-06-02
US7550619B2 (en) 2009-06-23
WO2004052310A2 (en) 2004-06-24
CN101899063B (en) 2012-12-12
KR100944063B1 (en) 2010-02-24
BRPI0317255B8 (en) 2021-05-25
CA2735485A1 (en) 2004-06-24
KR20050087831A (en) 2005-08-31
CN102675355A (en) 2012-09-19
CA2508811C (en) 2014-11-18
US20060106216A1 (en) 2006-05-18
BR0317255A (en) 2005-11-08
SI1644384T1 (en) 2013-02-28
BR122019020833B1 (en) 2020-09-01
KR101096830B1 (en) 2011-12-22
EP1644384B1 (en) 2012-10-31
US7034152B2 (en) 2006-04-25
MXPA05005971A (en) 2005-12-05
PL377263A1 (en) 2006-01-23
PT1644384E (en) 2013-01-23
IL168691A (en) 2011-09-27

Similar Documents

Publication Publication Date Title
IN2012DN00605A (en)
YU47600A (en) SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa
CA2293247A1 (en) 4-phenylpiperidine compounds
IL148932A0 (en) INHIBITORS OF αLβ2 MEDIATED CELL ADHESION
MXPA03009600A (en) Nociceptin analogs.
DE69831868D1 (en) Antithrombosemittel
PT1485359E (en) Sodium channel blockers
DE69931393D1 (en) ANTITHROMBOTIC AMIDE
PL354998A1 (en) Substituted oxoazaheterocyclyl compounds
TW200606137A (en) Urea derivatives
MX2007004698A (en) Asymmetric synthesis of substituted dihydrobenzofurans.
DK0443449T3 (en) Process for the production of oxetanones
UA74439C2 (en) Compounds of spiropyrazole
ATE273305T1 (en) THROMBIN INHIBITORS
EP1048652A4 (en) Aromatic compounds having cyclic amino or salts thereof
CY1110539T1 (en) METHOD FOR PHENYL ACID PRODUCERS
SG144736A1 (en) Synthesis of temozolomide and analogs
MY138051A (en) Compounds and processes
NO991501D0 (en) Hydroxyalkylation of phenols
WO2002053535A3 (en) Process for making amlodipine, derivatives thereof, and precursors therefor
EP1555261A4 (en) Valerolactone compounds and perfume composition
AU4682985A (en) 2-(3,5-Dislkyl -4- Hydroxyphenyl) indole derivatives
PL362885A1 (en) New carbazole compounds [3,4-a:3,4-c], method of manufacture of new carbazole compounds [3,4-a:3,4-c] as well as compound pharmaceuticals containing them
MY134226A (en) 1,2-dihydropyrazol-3-ones which control inflammatory cyctokines
MY133207A (en) Substituted benzolactam compaunds